Prediction Case File
YouTubeEvaluation Complete

SPDR S&P Biotech ETF ETF Prediction and Forecast [XBI]

1 extracted signal · 1 resolved · 0 still active

StockInvest.us profile imageStockInvest.usIndependent analyst profile
Source published
16 Aug 2025, 03:15 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for SPDR S&P Biotech ETF ETF Prediction and Forecast [XBI]
Source overview

AI-generated source summary

The analysis assesses XBI, an ETF holding several positive signals with a strong rising trend. The system ranks it as a strong buy candidate, a score of 7.3 as of August 15, 2025. Since August 12, 2025, the ETF has gained 4.33%, an average of 1.08% daily. Current analysis suggests a potential 10.29% increase in the next three months. Expected returns range from 4.25% to 11.87%. However, the 12-month analysis projects a potential decline of approximately 19.18%. A short term perspective shows a potential price range between 50.20 to 73.29. The latest daily update for XBI highlights, upgraded to a strong buy candidate after a recent increase. The recent day has risen by 1.24% which translates from 89.57 to 90.68. The ETF's 52 week high indicates 105.47. Positive signals included both short and long-term moving averages, as per volume analysis trading levels can find support at 87.51 and 86.44.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
1
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
100%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    1 eligible signal linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Analyst snapshot

StockInvest.us

Platform-wide history, separate from this source evaluation.

Reliability
53.4
Tracked signals
1779
Historical success
42.8%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail